Lepu Medical Technology (Beijing) (300003) Fundamentals 2026 — P/E 28.7x, Revenue Analysis | SniperIQ
Lepu Medical Technology (Beijing) (300003) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥23.8B, trading at ¥12.90 on the SHZ. This SniperIQ fundamentals page covers Lepu Medical Technology (Beijing)'s valuation (P/E 28.7x, P/B 1.4x), profitability (net margin 12.9%), revenue (¥6.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lepu Medical Technology (Beijing)'s market cap?
Lepu Medical Technology (Beijing) (300003) has a market capitalization of approximately ¥23.8B, trading at ¥12.90 on the SHZ. Market cap moves with the live share price.
What is Lepu Medical Technology (Beijing)'s P/E ratio?
Lepu Medical Technology (Beijing)'s trailing twelve-month P/E ratio is 28.7x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lepu Medical Technology (Beijing)?
Lepu Medical Technology (Beijing) runs a net profit margin of 12.9%, a gross margin of 63.4%, and an operating margin of 17.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lepu Medical Technology (Beijing) generate?
Lepu Medical Technology (Beijing) reported revenue of ¥6.5B for fiscal year 2025, with net income of ¥962M and earnings per share (EPS) of 0.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lepu Medical Technology (Beijing) pay a dividend?
Lepu Medical Technology (Beijing) offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Lepu Medical Technology (Beijing) financially healthy?
Lepu Medical Technology (Beijing) carries a debt-to-equity ratio of 0.35x and a current ratio of 2.38x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lepu Medical Technology (Beijing) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lepu Medical Technology (Beijing) (300003) the key facts are: market cap ¥23.8B, P/E 28.7x, revenue ¥6.5B, 52-week range 11.01-21.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lepu Medical Technology (Beijing)'s full fundamentals live
Get Lepu Medical Technology (Beijing)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.